NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026

NHS EnglandcontractFind a TenderRef ocds-h6vhtk-051c98Procurement Act 2023SME suitablepending
View buyer

Estimated value

Awarded value

£201.7m

Awarded 14 Jun 2026

Suppliers

27

6 SME

Lots

2

2 awarded

Published

23 Jun 2026

Description

NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Scope

Reference
C414060
Commercial tool
Standalone contract
Contract dates
31 Aug 2026 to 31 Aug 2028
Possible extension to 31 Aug 2030

With an option or option(s) to extend for a further 24 months.

CPV classifications
33600000
Contract locations
North East England, United Kingdom
North West England, United Kingdom
East Midlands, United Kingdom
West Midlands, United Kingdom
East of England, United Kingdom
London, United Kingdom
South East England, United Kingdom
South West England, United Kingdom
Particular suitability
Small and medium-sized enterprises (SME)

Award criteria

Criteria the buyer will use to evaluate bids.

NameDescriptionTypeWeighting
Price is not the only award criterionPrice is not the only award criterion and all criteria are stated only in the procurement documentsprice

Submission & procedure

Procedure
Open procedure

Award details· 2 awards

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

£166.3m

Award date

14 Jun 2026

Contract start

31 Aug 2026

Contract end

31 Aug 2028

Lots · 2 total

Divisions of the contract. Each lot can be awarded separately.

View all →
LotTitleEst. valueStatus
1CM/PHR/25/5730/01 - Tranche B for NOFE and MAE£846.1mcomplete
2CM/PHR/25/5730/02 - Natalizumab for London & SOFE£31.5mcomplete